SG11201808820QA - Methods and kits for the diagnosis and risk stratification of patients with ischemia - Google Patents
Methods and kits for the diagnosis and risk stratification of patients with ischemiaInfo
- Publication number
- SG11201808820QA SG11201808820QA SG11201808820QA SG11201808820QA SG11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA SG 11201808820Q A SG11201808820Q A SG 11201808820QA
- Authority
- SG
- Singapore
- Prior art keywords
- sant
- international
- ischemia
- pavello
- iccc
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 October 2017 (19.10.2017) WIPO I PCT (10) International Publication Number WO 2017/178521 Al 111111111111110111011111111111010111110111010111H11111010111111111110111111 (51) International Patent Classification: GO1N 33/68 (2006.01) (21) International Application Number: PCT/EP2017/058768 (22) International Filing Date: 12 April 2017 (12.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16382167.1 12 April 2016 (12.04.2016) EP (71) Applicants: INSTITUT CATALA DE CIENCIES CAR- DIOVASCULARS (ICCC) [ES/ES]; Hospital Santa Creu i Sant Pau, Pavello Antic Convent, Sant Antoni Maria Claret, 167, E-08025 Barcelona (ES). CONSEJO SU- PERIOR DE INVESTIGACIONES CIENTIFICAS; Serrano, 117, E-28006 Madrid, (ES). (72) Inventors: BADIMON MAESTRO, Lina; INSTITUT CATALA DE CIENCIES CARDIOVASCULARS (ICCC), Hospital Santa Creu i Sant Pau, Pavello Antic Convent Sant Antoni Maria Claret, 167, E-08025 Barcelona (ES). CUBEDO RAFOLS, Judit; INSTITUT CATALA DE CIENCIES CARDIOVASCULARS (ICCC), Hospital Santa Creu i Sant Pau, Pavello Antic Convent Sant Antoni Maria Claret, 167, E-08025 Barcelona (ES). PADRO CAPMANY, Teresa; INSTITUT CATALA DE CIEN- CIES CARDIOVASCULARS (ICCC), Hospital Santa Creu i Sant Pau, Pavello Antic Convent Sant Antoni Maria Claret, 167, E-08025 Barcelona (ES). (74) Agent: ALCONADA RODRIGUEZ„ Agustin; ABG PATENTES, S.L., Avda. de Burgos, 16D, Edificio EUR- OMOR, E-28036 Madrid (ES). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) W O 20 1717 / 85 21 Al (54) Title: METHODS AND KITS FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PATIENTS WITH ISCHEMIA (57) : The invention relates to methods for the diagnosis of ischemia or ischemic tissue damage, methods for predicting the progression of ischemia in a patient having suffered an ischemic event, for determining the prognosis of a patient having suffered an ischemic event and for determining the risk that a patient suffering from stable coronary disease suffers a recurrent ischemic event based on the detection of the levels of glycosylated Apo J. The invention relates as well to a method for the determination of glyc - osylated Apo J in a sample.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382167.1A EP3232200A1 (en) | 2016-04-12 | 2016-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
| PCT/EP2017/058768 WO2017178521A1 (en) | 2016-04-12 | 2017-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808820QA true SG11201808820QA (en) | 2018-11-29 |
Family
ID=56008566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808820QA SG11201808820QA (en) | 2016-04-12 | 2017-04-12 | Methods and kits for the diagnosis and risk stratification of patients with ischemia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11486884B2 (en) |
| EP (2) | EP3232200A1 (en) |
| JP (1) | JP7075894B2 (en) |
| KR (1) | KR102344344B1 (en) |
| CN (1) | CN109154620B (en) |
| AU (1) | AU2017251355A1 (en) |
| BR (1) | BR112018070971A2 (en) |
| CA (1) | CA3020666A1 (en) |
| IL (1) | IL262245B (en) |
| MA (1) | MA44658A (en) |
| MX (1) | MX2018012580A (en) |
| RU (1) | RU2750035C2 (en) |
| SG (1) | SG11201808820QA (en) |
| WO (1) | WO2017178521A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210388108A1 (en) * | 2018-10-23 | 2021-12-16 | Glycardial Diagnostics, S.L. | Antibodies specific for glycosylated apoj and uses thereof |
| CN113395994A (en) * | 2018-12-05 | 2021-09-14 | 格雷卡迪亚尔诊断有限公司 | Methods and compositions for preventing and/or treating ischemia and treating ischemia/reperfusion injury |
| KR102158726B1 (en) | 2019-04-17 | 2020-09-22 | 한림대학교 산학협력단 | DNA methylation marker composition for diagnosis of delayed cerebral ischemia comprising intergenic region of ITPR3 gene upstream |
| KR102281644B1 (en) | 2019-12-23 | 2021-07-23 | 한림대학교 산학협력단 | INSR Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102281657B1 (en) | 2019-12-23 | 2021-07-26 | 한림대학교 산학협력단 | CDHR5 Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102312534B1 (en) | 2019-12-31 | 2021-10-13 | 한림대학교 산학협력단 | A method for diagnosing delayed ischemia using a cerebrospinal fluid-derived mitochondrial marker |
| KR102318236B1 (en) | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | A method for diagnosing a delayed cerebral ischemia using the concentration of blood copeptin |
| KR102336507B1 (en) | 2020-02-21 | 2021-12-06 | 한림대학교 산학협력단 | A method for diagnosing a delayed cerebral ischemia using the regional oxygen saturation |
| KR102369155B1 (en) | 2020-07-07 | 2022-02-28 | 한림대학교 산학협력단 | A method for diagnosing a delayed cerebral ischemia using near infrared spectroscopy |
| KR102496589B1 (en) | 2020-09-11 | 2023-02-03 | 한림대학교 산학협력단 | VHL Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102473349B1 (en) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | KIFAP3 Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102473348B1 (en) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | KIF3A Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102473350B1 (en) | 2020-09-11 | 2022-12-05 | 한림대학교 산학협력단 | RACGAP1 Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102477501B1 (en) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | ALB Gene hypomethylation marker for diagnosis of delayed cerebral ischemia |
| KR102477502B1 (en) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | IL5 Gene hypomethylation marker for diagnosis of delayed cerebral ischemia |
| KR102477500B1 (en) | 2020-09-15 | 2022-12-14 | 한림대학교 산학협력단 | OPRM1 Gene hypermethylation marker for diagnosis of delayed cerebral ischemia |
| KR102470789B1 (en) | 2020-11-05 | 2022-11-25 | 한림대학교 산학협력단 | PINK1 biomarker for the diagnosis of delayed cerebral ischemia |
| KR102466956B1 (en) | 2020-11-05 | 2022-11-11 | 한림대학교 산학협력단 | DAPK1 biomarker for the diagnosis of delayed cerebral ischemia |
| KR102398533B1 (en) | 2020-11-05 | 2022-05-13 | 한림대학교 산학협력단 | Cerebrospinal fluid mitophagy markers for the diagnosis of delayed cerebral ischemia |
| KR102398534B1 (en) | 2020-11-05 | 2022-05-13 | 한림대학교 산학협력단 | BNIP3L biomarker for the diagnosis of delayed cerebral ischemia |
| CN113462744B (en) * | 2021-05-24 | 2023-06-23 | 中国药科大学 | Application of N-acetylglucosamine as marker in preparation of reagent for diagnosing ischemic cerebral apoplexy |
| KR20230022141A (en) | 2021-08-06 | 2023-02-14 | 에이치앤비지노믹스 주식회사 | A method and apparatus for providing information on the risk of developing complex diseases customized for each individual based on intelligent omics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140045A (en) | 1995-03-10 | 2000-10-31 | Meso Scale Technologies | Multi-array, multi-specific electrochemiluminescence testing |
| WO1999004260A1 (en) * | 1997-07-15 | 1999-01-28 | Bioprobes, Inc. | Determining alcohol intake using sialic acid/apo j |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| WO2005107491A2 (en) * | 2004-05-05 | 2005-11-17 | Northeastern University | Multi-lectin affinity chromatography and uses thereof |
| JP6028960B2 (en) * | 2009-07-14 | 2016-11-24 | 国立研究開発法人産業技術総合研究所 | Glycan markers for liver disease condition indicators |
| ES2364169B1 (en) | 2010-02-09 | 2012-07-10 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) | USE OF APO J ISOFORMS AS TISSULAR INJURY BIOMARKERS. |
| EP2400304A1 (en) | 2010-06-22 | 2011-12-28 | Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) | Method for the characterization of intermolecular interactions |
| JP2012107932A (en) | 2010-11-16 | 2012-06-07 | Mitsubishi Chemicals Corp | Inspection method of cerebral infarction with clusterin protein |
| BR112017021850A2 (en) | 2015-04-30 | 2018-07-10 | Idexx Lab Inc | clusterin specific isoforms detection |
| CN107957498A (en) * | 2016-10-18 | 2018-04-24 | 厦门德馨尚品医疗科技有限公司 | A kind of kit containing Apolipoprotein J and its application in clinical diagnosis |
-
2016
- 2016-04-12 EP EP16382167.1A patent/EP3232200A1/en not_active Withdrawn
-
2017
- 2017-04-12 US US16/092,703 patent/US11486884B2/en active Active
- 2017-04-12 SG SG11201808820QA patent/SG11201808820QA/en unknown
- 2017-04-12 KR KR1020187032609A patent/KR102344344B1/en active IP Right Grant
- 2017-04-12 MA MA044658A patent/MA44658A/en unknown
- 2017-04-12 CA CA3020666A patent/CA3020666A1/en active Pending
- 2017-04-12 AU AU2017251355A patent/AU2017251355A1/en not_active Abandoned
- 2017-04-12 EP EP17717159.2A patent/EP3443353B1/en active Active
- 2017-04-12 CN CN201780029342.8A patent/CN109154620B/en active Active
- 2017-04-12 JP JP2018554391A patent/JP7075894B2/en active Active
- 2017-04-12 RU RU2018139780A patent/RU2750035C2/en active
- 2017-04-12 BR BR112018070971A patent/BR112018070971A2/en not_active Application Discontinuation
- 2017-04-12 WO PCT/EP2017/058768 patent/WO2017178521A1/en active Application Filing
- 2017-04-12 MX MX2018012580A patent/MX2018012580A/en unknown
-
2018
- 2018-10-09 IL IL262245A patent/IL262245B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017178521A1 (en) | 2017-10-19 |
| RU2018139780A3 (en) | 2020-07-24 |
| EP3443353B1 (en) | 2024-03-13 |
| CN109154620B (en) | 2022-03-08 |
| CA3020666A1 (en) | 2017-10-19 |
| JP2019516966A (en) | 2019-06-20 |
| EP3443353A1 (en) | 2019-02-20 |
| RU2018139780A (en) | 2020-05-12 |
| BR112018070971A2 (en) | 2019-01-29 |
| KR102344344B1 (en) | 2021-12-28 |
| CN109154620A (en) | 2019-01-04 |
| US20190128900A1 (en) | 2019-05-02 |
| MX2018012580A (en) | 2019-02-25 |
| MA44658A (en) | 2019-02-20 |
| AU2017251355A1 (en) | 2018-11-08 |
| EP3232200A1 (en) | 2017-10-18 |
| IL262245A (en) | 2018-11-29 |
| RU2750035C2 (en) | 2021-06-21 |
| US11486884B2 (en) | 2022-11-01 |
| KR20190008216A (en) | 2019-01-23 |
| JP7075894B2 (en) | 2022-05-26 |
| IL262245B (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808820QA (en) | Methods and kits for the diagnosis and risk stratification of patients with ischemia | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11202000444PA (en) | Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets | |
| SG11201807501UA (en) | Method and system for imaging | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201810544WA (en) | Detecting hematological disorders using cell-free dna in blood | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201804440XA (en) | Chemical reprogramming of human glial cells into neurons with small molecule cocktail | |
| SG11201900133WA (en) | Adrenomedullin for assessing congestion in a subject with acute heart failure | |
| SG11201407208UA (en) | A method for dynamic generation and modification of an electronic entity architecture | |
| SG11201907844TA (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| SG11201903420SA (en) | Antisense oligonucleotides |